Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar' - Definium Therapeu

Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trials

Definium Therapeutics oral LSD candidate DT120 has passed a late-stage study in generalized anxiety disorder (GAD), not even two months after reporting trial success for in depression.